
About Tango Therapeutics
Tango Therapeutics (NASDAQ:TNGX) focuses on discovering and delivering transformative cancer therapies. With a commitment to leveraging the latest in scientific research to address unmet needs in oncology, Tango is dedicated to identifying and exploiting cancer vulnerabilities through a precision medicine approach. Their projects revolve around developing a diverse pipeline of innovative treatment options that aim to improve outcomes for patients with various cancer types. Operating at the intersection of groundbreaking science and patient-centric development, Tango's objectives include advancing these projects through clinical trials, securing regulatory approvals, and ultimately making these therapies available to the patients who need them the most.
Snapshot
Operations
Products and/or services of Tango Therapeutics
- Development of targeted cancer therapies using CRISPR-based functional genomics to identify novel drug targets.
- Advancement of a personalized cancer vaccine platform for various tumor types.
- Research on small molecule inhibitors targeting synthetic lethal interactions in cancer cells.
- Creation of a suite of bioinformatics tools for the analysis of cancer genomics data.
- Efforts in molecular diagnostics for early cancer detection and treatment decision support.
- Collaboration with pharmaceutical companies to co-develop and bring targeted cancer therapies to market.
Tango Therapeutics executive team
- Dr. Barbara L. Weber M.D.Founder & Executive Chair
- Dr. Malte Peters M.D.President, CEO & Director
- Ms. Daniella Beckman CPAChief Financial Officer
- Mr. Douglas J. Barry Esq., J.D.Chief Compliance Officer & Corporate Secretary
- Dr. Adam S. Crystal M.D., Ph.D.President of Research & Development
- Prof. Alan Ashworth FRS, Ph.D.Founder & Member of Scientific Advisory Board
- Dr. William G. Kaelin Jr., M.D.Founder & Member of Scientific Advisory Board
- Dr. Antoni Ribas M.D., Ph.D.Founder & Member of Scientific Advisory Board
- Dr. Michael Palmieri Ph.D.Chief Technical Operations Officer
- Mr. Jannik N. Andersen Ph.D.Chief Scientific Officer